Explore baxter.com

This site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative.

Renal Care EMEA

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Modern PD

    Modern PD offers patients many choices. Are you ready to voice them?

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx

    Innovative Expanded Hemodialysis (HDx) therapy is the next evolution in hemodialysis treatment.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Clinical Data

Clinical research lies at the heart of who we are. Baxter uses scientific evidence systematically, and transparently, to inform the development of new and state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Baxter. 

A Focus on Clinical Research

HDx

Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration - Leypoldt JK et al.

View resource
HDx

Large Middle Molecule and Albumin Removal: Why Should We Not Rest on Our Laurels? - Florens N et al.

View resource
HDx

Large uremic toxins: an unsolved problem in end-stage kidney disease - Wolley MJ and Hutchison CA.

View resource
HDx

Long-term effect of medium cut-off dialyzer on middle uremic toxins and cell-free hemoglobin - Cho N-J et al.

View resource
HDx

MCO Membranes: Enhanced Selectivity in High-Flux Class - Boschetti-de-Fierro A et al.

View resource
HDx

Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Tria - Zickler D et al.

View resource
HDx

Medium Cut-Off Dialyzer versus Eight Hemodiafiltration Dialyzers: Comparison Using a Global Removal Score - Maduell F et al.

View resource
HDx

Membrane Innovation in Dialysis - Boschetti-de-Fierro A et al.

View resource
HDx

Membrane innovation: closer to native kidneys - Storr M, Ward RA.

View resource
HDx

Performance of hemodialysis with novel medium cut-off dialyzers - Kirsch AH, et al.

Learn More
HDx

Pyrogen retention: Comparison of the novel medium cut-off (MCO) membrane with other dialyser membranes - Hulko M et al.

View resource
HDx

Quantification of Internal Filtration in Hollow Fiber Hemodialyzers with Medium Cut-Off Membrane - Lorenzin A et al.

View resource

Are you interested in additional information about ways in which we are transforming Renal Care through Patient-Centric Innovations?

Request information here

About Us
Baxter has been a front-runner in the treatment and management of end-stage kidney disease for over 85 years. Today, our state-of-the-art solutions for both hemodialysis and peritoneal dialysis are transforming global renal care. It’s why you can rely on us to be the type of dedicated partner who understands the challenges you face throughout the continuum of care to meet the individual needs of your patients.
 

Baxter, AK 98, AN69, Artis Physio Plus, BiCart, CWP 800, Evodial, Homechoice, Nephral ST, Novaline, Polyflux, Revaclear, Sharesource, Sharesource Adequest, SoftPac, SelectBag, Theralite and Theranova are trademarks of Baxter International Inc. or its subsidiaries.

©Copyright 2024 Baxter. All rights reserved.